Ajanta Pharma promoter trust releases 23.26 lakh pledged shares
Ravi Agrawal Trust cuts encumbered stake to 2.75% from 4.61%, citing excess pledge. The move trims total promoter group encumbrance to about 15% and follows a ₹1,046 cr share sale earlier this month.
— 5 earlier stories on Ajanta Pharma Ltd. →What's new
- Ravi Agrawal Trust released pledges on 23.26 lakh shares (1.86% of equity) on June 16.
- Trust's encumbered holding fell from 4.61% to 2.75%; promoter group encumbrance dropped to ~15% from 16.88%.
- Move follows 34.5 lakh share sale by same trust and recent pledge creations by other promoter entities.
Why this matters
Every percentage point of promoter pledge unwound reduces the overhang risk. For a debt-free pharma with 24.3% ROE, this is a quiet positive, though the prior share sale telegraphed it.
What we're watching
- Whether other promoter entities follow with more releases.
- Any further open-market sale from the trust after the June block.
- Impact on future pledge-creation activity; the group has been active on both sides.
The full read
Ajanta Pharma's promoter group just unfastened another piece of collateral. Ravi Agrawal Trust released pledges on 23.26 lakh shares (1.86% of equity) on June 16, trimming its own encumbered holding from 4.61% to 2.75% and the group's total to roughly 15% from 16.88%. The stated reason: excess pledge. It follows the same trust's sale of 34.5 lakh shares earlier in June, a ₹1,046 cr block that had already signalled deleveraging. For a company carrying zero debt and an ROE above 24%, each percentage point of pledge unwound is a marginal positive. The story here is not surprise. It's direction. The promoter group has been active on both sides of the pledge ledger this month; this release tips the balance toward reduction.
Questions answered
- How much of Ajanta Pharma's equity is now encumbered by promoters?
- After this release, the promoter group's total encumbered stake stands at about 15.02% of equity, down from 16.88% before June 16.
- Why did Ravi Agrawal Trust release the pledges?
- The trust cited 'excess pledge' as the reason, suggesting the shares were no longer needed as collateral – likely because the underlying loan was repaid or margin was freed after the earlier share sale.
- Does this change Ajanta Pharma's leverage profile?
- No. The company itself is debt-free. This is a promoter-level activity and does not affect the company's balance sheet or debt/equity ratio, which remains zero.
- Is this pledge release connected to the June 9 share sale?
- Probably. The same trust sold 34.5 lakh shares (2.76% equity) on June 9 for an estimated ₹1,046 cr. Reducing pledges after a large sale suggests the trust is deleveraging post-sale.
Ajanta Pharma Ltd.
Latest quarter · Mar 2026
Strength & growth
Story so far
All notes on AJANTPHARM →- 19 Jun 2026 · 2:27 PM IST Ajanta Pharma promoter trust releases 23.26 lakh pledged shares
- today Ajanta Pharma promoters pledge 13.5% equity to back ₹3,873 cr outside debt
- today Ajanta Pharma promoter pledges 10.06 lakh shares; encumbered stake at 10.83%
- 18d ago Ajanta Pharma promoter pledges additional 0.89% stake to RBL Bank
- 24d ago Ajanta Pharma promoter sells 2.76% stake for about ₹1,046 cr